Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Jul 28, 2006; 12(28): 4466-4472
Published online Jul 28, 2006. doi: 10.3748/wjg.v12.i28.4466
Published online Jul 28, 2006. doi: 10.3748/wjg.v12.i28.4466
Table 3 Randomised controlled trials of adjuvant treatment for pancreatic ductal adenocarcima
Trial | Comparison | Adjuvant treatment | Number of patients | Conclusions |
GITSG, 1985[58], 1987[59] | CRT vs OBS | 2 × (20 Gy in 10 fractions + 500 mgm-2 5FU d 1-3) + weekly 5FU to recurrence | 49 pancreatic patients randomised | Significant increase in median survival (20 vs 11 mo, P = 0.035) in 43 eligible patients |
Norway, 1993[60] | CT vs OBS | AMF (40 mgm-2 doxorubicin, 6 mgm-2 mytomycin C, 500 mgm-2 5FU) once every 3 wk for six courses | 61 patients (47 pancreatic, 14 ampullary) randomised 46 additional nonrandomised patients | Significant increase in median survival (23 vs 11 mo, P = 0.02) in 60 pancreatic and ampullary patients combined |
EORTC, 1999[61] | CRT vs OBS | 2 × (20 Gy in 10 fractions + 25 mgkg-1 5FU/FA d 1-5) | 218 patients (120 pancreatic, 93 ampullary) randomised | NS increase in median survival (25 vs 19 mo, P = 0.21) in 207 eligible patients NS increase in median survival in 114 eligible pancreatic patients (17 vs 13 mo, P = 0.099) |
Japan, 2002[62] | CT vs OBS | 6 mgm-2 mytomycin C d 1 + 310 mgm-2 5FU d 1-5 and d 15-20 followed by 100 mgm-2 oral 5FU daily until recurrence | 508 patients (173 pancreatic, 335 bile duct/gallbladder/ampullary) randomised | Significant survival benefit in gallbladder No difference in 158 eligible pancreatic patients No difference in 48 eligible ampullary patients |
ESPAC1, 2001[63], 2004[64] | CRT vs no CRT CT vs no CT | 2 × (20 Gy in 10 fractions + 500 mgm-2 5FU/FA d 1-3)(20 mgm-2 FA + 425 mgm-2 5FU d 1-5) × six cycles | 289 pancreatic patients randomised | NS decrease in survival for CRT (P = 0.05) in 289 patients Significant increase in survival for CT (P = 0.009) in 289 eligible patients |
CONKO-001, 2005[65] | CT vs OBS | 1 gm-2 GEM, d 1, 8, 15, every 4 wk for 6 mo | 368 pancreatic patients randomised | Significant increase in median DFS (14.2 vs 7.5 mo, P < 0.05) in 356 eligible patients |
- Citation: Nakao A, Fujii T, Sugimoto H, Kanazumi N, Nomoto S, Kodera Y, Inoue S, Takeda S. Oncological problems in pancreatic cancer surgery. World J Gastroenterol 2006; 12(28): 4466-4472
- URL: https://www.wjgnet.com/1007-9327/full/v12/i28/4466.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i28.4466